Abstract
Currently, there are no specific recommendations regarding the management of the synchronous tumours due to the lack of either specific guidelines or individuals' clinical experiences relative to these clinical situations. In the presence of a locally advanced double primary tumour and with the lymph node metastases in addition, from the radiotherapeutical point of view, it must be challenging to manage this complicated situation that requires a more delicate treatment planning, due to higher doses prescribed to greater volumes concomitantly with the chemotherapy. A 68-year-old Caucasian male with a synchronous intermediate-risk prostate adenocarcinoma and locally advanced anal canal carcinoma underwent IMRT-SIB with concomitant chemotherapy at our institute. Two years after the treatment, the restaging CT and MRI scan showed no evidence of the disease and the patient reported no significant gastrointestinal or genitourinary toxicity. Our experience is unique, since it is the first report on using the IMRT-SIB technique simultaneously with chemotherapy in the management of the synchronous prostate and anal canal carcinomas. Therefore, we find it important to provide the current literature with the results from our experience which show good feasibility, efficacy, and tolerability of the definitive concomitant IMRT-SIB-chemotherapy for the synchronous anal canal cancer and prostate cancer.
Highlights
Speaking, synchronous tumours are very rare clinical entities, and for that reason, the recommendations for their treatment, as well as the epidemiological data, are still lacking in the available papers
A 68-year-old Caucasian male with a synchronous intermediate-risk prostate adenocarcinoma and locally advanced anal canal carcinoma underwent intensitymodulated radiation therapy (IMRT)-SIB with concomitant chemotherapy at our institute
Two years after the treatment, the restaging computed tomography (CT) and magnetic resonance imaging (MRI) scan showed no evidence of the disease and the patient reported no significant gastrointestinal or genitourinary toxicity
Summary
Synchronous tumours are very rare clinical entities, and for that reason, the recommendations for their treatment, as well as the epidemiological data, are still lacking in the available papers. For the eventual prostate and anal canal synchronous cancers, the epidemiological data does not exist at all, due to an extremely rare clinical situation. By considering those tumours separately, it has already been well established that the prostate cancer is the most common cancer in Europe for males [2], while the anal canal carcinoma is much less common. We thought that reporting the results of our experience shall be interesting, due to the lack of either specific guidelines or individuals’ clinical experiences relative to these kinds of clinical situations, and it can provide the currently available papers with the results on feasibility, efficacy, and tolerability of the definitive concomitant IMRTSIB-chemotherapy for the synchronous locally advanced anal canal cancer and intermediate-risk prostate cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
